Duchenne Muscular Dystrophy Management and Treatment Access Challenges:
Case Report

Tarek   I.   El-Azzabi

doi:10.2174/04666230105120905

Abstract

Introduction: Duchenne muscular dystrophy (DMD) is a rare neuromuscular disease that causes muscle weakness with respiratory and cardiac complications. International DMD standard of care guidelines exist, but their implementation and DMD treatment access in the Middle East have historically been challenging. This report highlights sub-optimal management of DMD in the Middle East together with recommendations for best practice, and the first reported use of ataluren, a mutation-specific treatment for nonsense mutation DMD (nmDMD), in this region.

Case Presentation: The management of two patients in the United Arab Emirates diagnosed with nmDMD is described. Under multidisciplinary care, both patients were treated with corticosteroids as per international DMD standard of care guidelines. Although both patients presented with typical DMD signs/symptoms, one received a genetic diagnosis and treatment relatively late owing to low awareness of the early signs and symptoms of DMD among physicians in the region; delayed genetic diagnosis of DMD hinders early initiation of mutation-specific treatments such as ataluren. Moreover, this patient demonstrated low adherence to the treatment plan, potentially resulting from low DMD awareness and poor understanding of the benefit-risk of corticosteroids in the patient’s family. In contrast, the other patient was genetically diagnosed early at 25 months, was administered ataluren whilst ambulatory, and demonstrated high adherence to the management plan. Limited expertise in performing motor function assessments and complications with medical insurance for ataluren in the region created additional obstacles in the management of both patients.

Conclusions: The contrasting experiences of these patients highlight the high variability of diagnosis and management of DMD in the Middle East. There is a need in the region to boost disease education for both public and professional communities, establish local DMD networks and guidelines, and improve access to treatments to improve the quality of care that patients with DMD receive.

[1]
Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management. Lancet Neurol  2010; 9(1): 77-93.
 [http://dx.doi.org/10.1016/S1474-4422(09)70271-6] [PMID: 19945913]

[2]
Ellis JA, Vroom E, Muntoni F. 195th ENMC International Workshop: Newborn screening for Duchenne muscular dystrophy December 14–16, 2012, Naarden, The Netherlands. Neuromuscul Disord  2013; 23(8): 682-9.
 [http://dx.doi.org/10.1016/j.nmd.2013.05.008] [PMID: 23791627]

[3]
Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol  2018; 17(3): 251-67.
 [http://dx.doi.org/10.1016/S1474-4422(18)30024-3] [PMID: 29395989]

[4]
Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J, Lochmüller H. Life expectancy at birth in Duchenne muscular dystrophy: A systematic review and meta-analysis. Eur J Epidemiol  2020; 35(7): 643-53.
 [http://dx.doi.org/10.1007/s10654-020-00613-8] [PMID: 32107739]

[5]
McDonald CM, Henricson EK, Abresch RT, et al. The cooperative international neuromuscular research group duchenne natural history study-a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used. Muscle Nerve  2013; 48(1): 32-54.
 [http://dx.doi.org/10.1002/mus.23807] [PMID: 23677550]

[6]
McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: A prospective cohort study. Lancet  2018; 391(10119): 451-61.
 [http://dx.doi.org/10.1016/S0140-6736(17)32160-8] [PMID: 29174484]

[7]
Barber BJ, Andrews JG, Lu Z, et al. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy. J Pediatr  2013; 163(4): 1080-1084.e1.
 [http://dx.doi.org/10.1016/j.jpeds.2013.05.060] [PMID: 23866715]

[8]
European Medicines Agency. Translarna™ (ataluren) summary of product characteristics. 2020. Available from: https://www.ema.europa.eu/en/documents/product-information/translarna-epar-product-information_en.pdf

[9]
Pichavant C, Aartsma-Rus A, Clemens PR, et al. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther  2011; 19(5): 830-40.
 [http://dx.doi.org/10.1038/mt.2011.59] [PMID: 21468001]

[10]
Jumah MA, Muhaizea MA, Rumayyan AA, et al. Current management of Duchenne muscular dystrophy in the Middle East: Expert report. Neurodegener Dis Manag  2019; 9(3): 123-33.
 [http://dx.doi.org/10.2217/nmt-2019-0002] [PMID: 31166138]

[11]
Alghamdi F, Al-Tawari A, Alrohaif H, et al. Case Report: The genetic diagnosis of duchenne muscular dystrophy in the Middle East. Front Pediatr  2021; 9: 716424.
 [http://dx.doi.org/10.3389/fped.2021.716424] [PMID: 34595143]

[12]
López-Hernández LB, Gómez-Díaz B, Escobar-Cedillo RE, et al. Duchenne muscular dystrophy in a developing country: Challenges in management and genetic counseling. Genet Couns  2014; 25(2): 129-41.
 [PMID: 25059011]